Published in J Biol Chem on February 02, 2015
PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget (2016) 0.79
Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis. J Thorac Oncol (2016) 0.76
MicroRNA-1304 suppresses human non-small cell lung cancer cell growth in vitro by targeting heme oxygenase-1. Acta Pharmacol Sin (2016) 0.75
Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib. Onco Targets Ther (2015) 0.75
Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma. World J Gastroenterol (2016) 0.75
Functional characterisation of bone marrow-derived mesenchymal stromal cells from COPD patients. ERJ Open Res (2016) 0.75
The Clinical Impact of Transcatheter Arterial Chemoembolization (TACE)-Induced c-Met Upregulation on TACE Refractoriness in Hepatocellular Carcinoma. Dig Dis Sci (2016) 0.75
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res (2006) 8.21
Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev (2006) 7.76
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Targeting MET in cancer: rationale and progress. Nat Rev Cancer (2012) 6.43
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res (2005) 4.94
Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol (2013) 4.72
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res (2007) 4.41
A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell (1994) 4.10
Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature (1999) 3.99
Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther (2011) 3.53
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res (2007) 3.23
Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol Cell Biol (1996) 2.69
Heme oxygenase-1: a provenance for cytoprotective pathways in the kidney and other tissues. Kidney Int (2006) 2.66
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother (2004) 2.42
Renal response to tissue injury: lessons from heme oxygenase-1 GeneAblation and expression. J Am Soc Nephrol (2000) 2.00
Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol (2010) 1.98
Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. J Clin Invest (2007) 1.67
Heme oxygenase-1 in tumor biology and therapy. Curr Drug Targets (2010) 1.67
HGF/SF-Met signaling in tumor progression. Cell Res (2005) 1.61
Coupling Met to specific pathways results in distinct developmental outcomes. Mol Cell (2001) 1.61
Heme regulates gene expression by triggering Crm1-dependent nuclear export of Bach1. EMBO J (2004) 1.49
Myeloid heme oxygenase-1 regulates innate immunity and autoimmunity by modulating IFN-beta production. J Exp Med (2009) 1.49
Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res (2006) 1.43
NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α. Cancer Res (2011) 1.41
c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem (2007) 1.34
c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol (2012) 1.33
HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene (2012) 1.20
HO-1-STAT3 axis in mouse liver ischemia/reperfusion injury: regulation of TLR4 innate responses through PI3K/PTEN signaling. J Hepatol (2011) 1.19
Overexpression of the met/HGF receptor in renal cell carcinomas. Int J Cancer (1996) 1.18
Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A (2010) 1.16
Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. Cancer Res (2006) 1.16
Activation of Ras by receptor tyrosine kinases. J Am Soc Nephrol (1994) 1.14
Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma. Clin Cancer Res (2006) 1.10
Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res (1999) 1.09
Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells. Cancer Res (2009) 1.04
The heme oxygenase-1 protein is overexpressed in human renal cancer cells following activation of the Ras-Raf-ERK pathway and mediates anti-apoptotic signal. J Biol Chem (2011) 1.02
Activated H-ras oncogenes in human kidney tumors. Cancer Res (1988) 0.99
The HGF receptor/Met tyrosine kinase is a key regulator of dendritic cell migration in skin immunity. J Immunol (2012) 0.94
Hepatocyte growth factor prevents multiple organ injuries in endotoxemic mice through a heme oxygenase-1-dependent mechanism. Biochem Biophys Res Commun (2009) 0.92
A novel CXCR3-B chemokine receptor-induced growth-inhibitory signal in cancer cells is mediated through the regulation of Bach-1 protein and Nrf2 protein nuclear translocation. J Biol Chem (2013) 0.90
Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clin Cancer Res (2004) 0.87
Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor. J Med Invest (2008) 0.85
The role of hepatocyte growth factor/c-met interactions in the immune system. Arch Immunol Ther Exp (Warsz) (2003) 0.83
A novel role for Bruton's tyrosine kinase in hepatocyte growth factor-mediated immunoregulation of dendritic cells. J Biol Chem (2011) 0.83
Chromosomal abnormalities of clear cell renal cell carcinoma: frequent gain of chromosome 7. Pathol Int (2010) 0.82
Improvement of sepsis by hepatocyte growth factor, an anti-inflammatory regulator: emerging insights and therapeutic potential. Gastroenterol Res Pract (2012) 0.81